S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Even at $2,000+ Per Share, These 3 Stocks Are Deals
Will NIO Partake In China's Economic Awakening?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Tax Software Specialist Vertex In Buy Zone After Base Breakout
How to Choose a Brokerage Account or Online Broker
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Even at $2,000+ Per Share, These 3 Stocks Are Deals
Will NIO Partake In China's Economic Awakening?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Tax Software Specialist Vertex In Buy Zone After Base Breakout
How to Choose a Brokerage Account or Online Broker
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Even at $2,000+ Per Share, These 3 Stocks Are Deals
Will NIO Partake In China's Economic Awakening?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Tax Software Specialist Vertex In Buy Zone After Base Breakout
How to Choose a Brokerage Account or Online Broker
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
3 EV Stocks You Need To Have On Your Watchlist
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Even at $2,000+ Per Share, These 3 Stocks Are Deals
Will NIO Partake In China's Economic Awakening?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Tax Software Specialist Vertex In Buy Zone After Base Breakout
How to Choose a Brokerage Account or Online Broker
NASDAQ:XBIT

XBiotech (XBIT) Stock Forecast, Price & News

$5.45
-0.05 (-0.91%)
(As of 06/9/2023 ET)
Compare
Today's Range
$5.30
▼
$5.63
50-Day Range
$3.06
▼
$5.76
52-Week Range
$3.00
▼
$6.49
Volume
54,674 shs
Average Volume
207,301 shs
Market Capitalization
$165.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

XBIT stock logo

About XBiotech (NASDAQ:XBIT) Stock

XBiotech, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutic antibodies. Its product pipeline includes oncology, infectious diseases, dermatology and inflammatory disorders. The company was founded by John Simard on March 22, 2005 and is headquartered in Austin, TX.

Receive XBIT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for XBiotech and its competitors with MarketBeat's FREE daily newsletter.

XBIT Stock News Headlines

June 3, 2023 | americanbankingnews.com
XBiotech (NASDAQ:XBIT) Coverage Initiated at StockNews.com
May 30, 2023 | americanbankingnews.com
XBiotech Inc. (NASDAQ:XBIT) Short Interest Up 23.1% in May
June 10, 2023 | Behind the Markets (Ad)
"Unknown laser company making HUGE profit from Russia-Ukraine War"
On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>
May 29, 2023 | americanbankingnews.com
XBiotech (NASDAQ:XBIT) and Cue Biopharma (NASDAQ:CUE) Financial Comparison
May 23, 2023 | finanznachrichten.de
XBiotech Inc.: FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients
May 22, 2023 | finance.yahoo.com
FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients
May 19, 2023 | americanbankingnews.com
XBiotech (NASDAQ:XBIT) Now Covered by StockNews.com
May 17, 2023 | finanznachrichten.de
XBiotech Inc.: XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares
June 10, 2023 | Behind the Markets (Ad)
"Unknown laser company making HUGE profit from Russia-Ukraine War"
On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>
May 17, 2023 | finance.yahoo.com
XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares
May 10, 2023 | americanbankingnews.com
XBiotech (NASDAQ:XBIT) Coverage Initiated by Analysts at StockNews.com
April 17, 2023 | finanznachrichten.de
XBiotech Inc.: XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
April 17, 2023 | finance.yahoo.com
XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
April 9, 2023 | finance.yahoo.com
XBiotech Inc.'s (NASDAQ:XBIT) top owners are individual investors with 51% stake, while 36% is held by insiders
April 5, 2023 | americanbankingnews.com
XBiotech (NASDAQ:XBIT) Now Covered by Analysts at StockNews.com
March 26, 2023 | americanbankingnews.com
StockNews.com Upgrades XBiotech (NASDAQ:XBIT) to "Hold"
February 15, 2023 | finance.yahoo.com
The past three years for XBiotech (NASDAQ:XBIT) investors has not been profitable
November 11, 2022 | finance.yahoo.com
XBiotech Third Quarter 2022 Earnings: US$0.42 loss per share (vs US$0.11 loss in 3Q 2021)
October 31, 2022 | finance.yahoo.com
Insiders own 35% of XBiotech Inc. (NASDAQ:XBIT) shares but individual investors control 47% of the company
October 18, 2022 | prnewswire.com
Helicobacter pylori Infection Market to Exhibit Growth at a Paltry CAGR of 1.9% During the Forecast Period (2022-2032) | DelveInsight - PR Newswire
October 13, 2022 | finance.yahoo.com
XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer - Yahoo Finance
October 13, 2022 | globenewswire.com
XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer - GlobeNewswire
October 13, 2022 | finance.yahoo.com
XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer
September 8, 2022 | finance.yahoo.com
XBiotech (NASDAQ:XBIT) shareholders have endured a 73% loss from investing in the stock a year ago
September 2, 2022 | nasdaq.com
We Think XBiotech (NASDAQ:XBIT) Can Afford To Drive Business Growth - Nasdaq
August 14, 2022 | finance.yahoo.com
We Think XBiotech (NASDAQ:XBIT) Can Afford To Drive Business Growth - Yahoo Finance
August 10, 2022 | marketscreener.com
XBIOTECH INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) | MarketScreener - Marketscreener.com
See More Headlines

XBIT Price History

XBIT Company Calendar

Today
6/10/2023
Next Earnings (Estimated)
6/13/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XBIT
CUSIP
N/A
CIK
1626878
Web
www.xbiotech.com
Phone
(512) 386-2900
Fax
512-386-5505
Employees
97
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($1.19)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-32,900,000.00
Net Margins
-820.45%
Pretax Margin
-882.82%
Return on Equity
-12.81%
Return on Assets
-12.46%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
59.78
Quick Ratio
59.78

Sales & Book Value

Annual Sales
$4.01 million
Price / Sales
41.37
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.90 per share
Price / Book
0.69

Miscellaneous

Outstanding Shares
30,440,000
Free Float
21,794,000
Market Cap
$165.90 million
Optionable
Optionable
Beta
1.21

Key Executives

  • John SimardJohn Simard
    Chairman, President & Chief Executive Officer
  • Ashley Otero
    Vice President-Clinical Operations
  • Angela Hu
    Chief Financial & Accounting Officer
  • Sushma Shivaswamy
    Chief Scientific Officer
  • Mark Ziats
    Medical Director

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













XBIT Stock - Frequently Asked Questions

How have XBIT shares performed in 2023?

XBiotech's stock was trading at $3.51 at the start of the year. Since then, XBIT shares have increased by 55.3% and is now trading at $5.45.
View the best growth stocks for 2023 here.

When is XBiotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 13th 2023.
View our XBIT earnings forecast.

What is John Simard's approval rating as XBiotech's CEO?

20 employees have rated XBiotech Chief Executive Officer John Simard on Glassdoor.com. John Simard has an approval rating of 58% among the company's employees. This puts John Simard in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of XBiotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other XBiotech investors own include Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Walt Disney (DIS), Cisco Systems (CSCO), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Intel (INTC), Pfizer (PFE) and Block (SQ).

When did XBiotech IPO?

(XBIT) raised $76 million in an initial public offering on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $18.00-$20.00 per share. WR Hambrecht + Co served as the underwriter for the IPO.

What is XBiotech's stock symbol?

XBiotech trades on the NASDAQ under the ticker symbol "XBIT."

Who are XBiotech's major shareholders?

XBiotech's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Dimensional Fund Advisors LP (0.25%), Connor Clark & Lunn Investment Management Ltd. (0.19%), Two Sigma Investments LP (0.18%), Renaissance Technologies LLC (0.17%), Two Sigma Advisers LP (0.16%) and Susquehanna International Group LLP (0.13%). Insiders that own company stock include John Simard, Queena Han, Street Financial SA Bay, Sushma Shivaswamy and W Thorpe Mckenzie.
View institutional ownership trends.

How do I buy shares of XBiotech?

Shares of XBIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is XBiotech's stock price today?

One share of XBIT stock can currently be purchased for approximately $5.45.

How much money does XBiotech make?

XBiotech (NASDAQ:XBIT) has a market capitalization of $165.90 million and generates $4.01 million in revenue each year. The biopharmaceutical company earns $-32,900,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis.

How can I contact XBiotech?

XBiotech's mailing address is 5217 Winnebago Ln, AUSTIN TX, 78744. The official website for the company is www.xbiotech.com. The biopharmaceutical company can be reached via phone at (512) 386-2900, via email at swhitehurst@xbiotech.com, or via fax at 512-386-5505.

This page (NASDAQ:XBIT) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -